YILIMART - T Cell TransAct

T Cell TransAct™ has been developed as a ready-to-use reagent to activate and expand human T cells via CD3 and CD28. Its polymeric nanomatrix structure ensures gentle and efficient activation of resting T cells from PBMCs and of enriched T cell populations, while maintaining high viability.

Background information

T Cell TransAct™ consists of a colloidal polymeric nanomatrix conjugated to humanized CD3 and CD28 agonists providing primary and co-stimulatory signals for an optimized and efficient T cell activation and expansion. The nanoscale structure of T Cell TransAct™ allows sterile filtration and excess reagent can be removed by centrifugation with following conventional supernatant replacement or simply by medium wash.

Polyclonal T cell expansion can be used when increased numbers of effector cells are required without the use of feeder cells or antigens, or when T cells are activated to enable gene modification.

Applications

In vitro

stimulation and expansion of T cell populations, either from purified T cells or from PBMCs.

Figure 1

Human purified T cells were isolated using the Pan T Cell Isolation Kit and activated for 48 hours using the T Cell TransAct™ (titer 1:100) in TexMACS™ Medium supplemented with Human IL-2 (20 IU/mL). The negative control experiment was performed without adding the T Cell TransAct. Cells were fluorescently stained using CD25-PE and CD69-APC and analyzed by flow cytometry using the MACSQuant® Analyzer. CD4-VioBlue

^®

was used for selection of T helper cells and CD8-VioGreen™ was used for selection of cytotoxic T cells. Dead cells and debris were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Negative control